I-Remdesivir umuthi we-antiviral oqondise uhla lwamagciwane. Yasungulwa ekuqaleni eminyakeni eyishumi edlule ukuze yelaphe i-hepatitis C kanye negciwane elifana nokubanda elibizwa ngokuthi i-respiratory syncytial virus (RSV). I-Remdesivir ibingeyona indlela yokwelapha esebenzayo yanoma yisiphi isifo. Kodwa yabonisa isithembiso ngokumelene namanye amagciwane.

Abacwaningi bahlole i-remdesivir ezivivinyweni zomtholampilo ngesikhathi sokuqubuka kwe-Ebola. Eminye imithi yophenyo yayisebenza kangcono, kodwa kwaboniswa ukuthi iphephile ezigulini. Ucwaningo kumaseli nasezilwaneni luphakamise ukuthi i-remdesivir ibisebenza ngempumelelo ekulweni namagciwane emndenini we-coronavirus, njenge-Middle East Respiratory Syndrome (MERS) kanye ne-Severe Acute Respiratory Syndrome (SARS).

I-Remdesivir isebenza ngokuphazamisa ukukhiqizwa kwegciwane. AmaCoronavirus anezakhi zofuzo ezenziwe i-ribonucleic acid (RNA). I-Remdesivir iphazamisa enye yama-enzyme abalulekile igciwane eliwadingayo ukuze liphindaphinde i-RNA. Lokhu kuvimbela igciwane ukuthi lingaphindaphindeki.

Abaphenyi baqale isivivinyo esingahleliwe, esilawulwayo se-antiviral ngoFebhuwari 2020 ukuze bahlole ukuthi i-remdesivir ingasetshenziswa yini ukwelapha i-SARS-CoV-2, i-coronavirus ebangela i-COVID-19. Ngo-April,imiphumela yokuqalaiveze ukuthi i-remdesivir isheshise ukululama ezigulini ezilaliswe esibhedlela ezine-COVID-19 enzima. Kube umuthi wokuqala ukuthola imvume yokusebenzisa izimo eziphuthumayo kwa-US Food and Drug Administration (FDA) ukwelapha abantu abalaliswe esibhedlela nge-COVID-19.

Abacwaningi manje sebeqedile ukuhlola, okwaziwa nge-Adaptive COVID-19 Treatment Trial (ACTT-1). Lolu cwaningo beluxhaswe yiNational Institute of Allergy and Infectious Diseases (NIAID). Umbiko wokugcina uvele kuI-New England Journal of Medicinengo-Okthoba 8, 2020.